Jpmorgan Chase & CO Belite Bio, Inc Call Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
12Shares Held
58.3KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA16.7KShares$830,1660.0% of portfolio
-
Marshall Wace, LLP London, X010.6KShares$527,0830.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.7KShares$433,2600.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$333,6600.0% of portfolio
-
Morgan Stanley New York, NY6.09KShares$303,2820.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.24B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...